Astrazeneca (AZN) Receivables Refunds (2016 - 2026)

Astrazeneca has reported Receivables Refunds over the past 17 years, most recently at $1.5 billion for Q1 2026.

For Q1 2026, Receivables Refunds fell 2.04% year-over-year to $1.5 billion; the TTM value through Mar 2026 reached $1.5 billion, down 2.04%, while the annual FY2025 figure was -$300.0 million, 80.72% down from the prior year.
Receivables Refunds for Q1 2026 was $1.5 billion at Astrazeneca, up from $1.4 billion in the prior quarter.
Over five years, Receivables Refunds peaked at $1.9 billion in Q4 2024 and troughed at -$1.2 billion in Q2 2025.
A 5-year average of $609.7 million and a median of $731.0 million in 2022 define the central range for Receivables Refunds.
On a YoY basis, Receivables Refunds climbed as much as 700.0% in 2022 and fell as far as 353.99% in 2022.
Year by year, Receivables Refunds stood at $731.0 million in 2022, then skyrocketed by 95.08% to $1.4 billion in 2023, then soared by 30.36% to $1.9 billion in 2024, then decreased by 25.17% to $1.4 billion in 2025, then grew by 10.21% to $1.5 billion in 2026.
Business Quant data shows Receivables Refunds for AZN at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.

Peer Comparison